NovoCure Limited · NASDAQ:NVCR

NovoCure — Investor Presentation (February 2024)

33 slides from NovoCure's investor presentation, February 2024

  1. Slide 1: © s oO & = = AW = ise) ror

    © s 2 oO & = = AW = ise) ror

  2. Slide 2: Forward-looking statements

    novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a

  3. Slide 3: 2023 achievements and 2024 milestones ahead

    2025 achievements and 2024 milestones ahead DRIVING COMMERCIAL ADVANCING ADOPTION CLINICAL TRIALS 2023 France reimbursement LUNAR data presented New array launched ACHIEVEMENTS — achieved and launch LUNAR U.S. FDA PMA, CE Mark in Europe and Japanese PMDA submitted New array FDA PMA METIS enrollment

  4. Slide 4: Together with our patients, we strive to extend survival

    together with our patients, we Strive to extend survival in some of the most aggressive forms of cancer patientforward’ To 2i24Novocure GmbH.

  5. Slide 5: Tumor Treating Fields selectively tuned electric fields kill cancer cells

    novocure’ Tumor Treating Fields (TTFields) are selectively tuned electric fields that exert physical forces to kill cancer cells TUNED ELECTRIC FIELDS DISRUPT PROTEINS DURING CELL DIVISION CAUSING CANCER CELL DEATH TTFields 100 to 500 kHz tumor cell healthy cell patientforward® © 2024Novocure GmbH 5

  6. Slide 6: Optune Gio wearable cancer therapy system

    novecure’ Optune Gio® wearable cancer therapy system DELIVERS CONTINUOUS TUMOR TREATING FIELDS THERAPY TO SOLID TUMORS TWO PRIMARY COMPONENTS electric field generator and transducer arrays TTT ae patientforward” Optune Gio? is intended as a treatment for adult patients (22 years of age or older) wit

  7. Slide 7: Strategy for long-term growth

    novecure’ Strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy patientforward” © 2024 Novocure GmbH 7

  8. Slide 8: Three focused objectives in 2024

    three focused objectives in 2024 JY{OPTUNE cio” LAUNCH LUNG DELIVER PIPELINE \ SESa ss forward’ GEM, alioblastoma

  9. Slide 9: Optune Gio: established in glioblastoma

  10. Slide 10: Optune Gio is proven to extend patient survival

    novecure’ Optune Gio is proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) oT Boon TN A rons | 202 | 360 NEARLY HALF 0.9 7) Log-rank P-value <0.001 43 % Si pespia win 08 4 HR (95% Cl) 0.63 (0.53-0.76) (0) . ig 07 exec Hedi

  11. Slide 11: Optune Gio: greater exposure increased survival

    novecure’ Optune Gio: greater exposure increased survival 25 months p<0.05 22 months p<0.05 20 months P<0.05 OF PATIENTS RECEIVED A SURVIVAL ' econ BENEFIT FROM OPTUNE GIO BECAUSE "46 months THEY USED IT >50% OF THE TIME 10 20 30 Median Overall Survival, months ANNUAL SURVIVAL RATE OF HIGHEST USAGE

  12. Slide 12: Real-world evidence demonstrates long and durable survival benefit

    novecure’ real-world evidence demonstrates long and durable survival benefit with Optune Gio, consistent with EF-14 il eee OVERALL SURVIVAL FOR U.S. PATIENTS FROM OPTUNE GIO START (N=974) 4 1% e) POST-PROGRESSION SURVIVAL FOR PATIENTS CONTINUING OPTUNE GIO (N=59)4 24% ar) mee (10 LOXICILy INCREASE O

  13. Slide 13: Phase 3 LUNAR trial in NSCLC met primary endpoint

    novecure’ phase 3 LUNAR trial in NSCLC met primary endpoint STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS 10 Median OS (months) 13.2 | 99 13.2 months o9 4 Log-rank P-value 0.035, . . HR (95% Cl) 0.74 (0.56-0.98) mOS with TTFields + SOC 08 4 3-year survival (95% Cl) 18% (11-27

  14. Slide 14: Significant opportunity to treat NSCLC patients

    Significant opportunity to treat NSCLC patients 114K stage IV NSCLC 1L patients in the U.S. ~3 0,000 >7 YEARS since any therapy 60% has shown a significant improvement in overall survival in 50% 2L NSCLC receive 1L platinum-based chemotherapy progress and seek 2L treatment forward © 2024Novocure Gmb

  15. Slide 15: Preparing for 2024 NSCLC launch

    novecure’ preparing for 2024 NSCLC launch b, 2023 5 2024 2025 L COMMERCIAL LAUNCH REGULATORY PATHWAY v HCP and patient campaigns y, _ , , v DTC campaign CLINICAL DATA Technical file submitted in EU V Global advisory boards v¥ PMA accepted for review at FDA v Announced top-line results . ; v KOL enga

  16. Slide 16: Phase 3 trial top-line data anticipated in 2024

    novecure’ phase S trial top-line data anticipated in 2024 | PANOVA-3 Pancreatic Cancer TTFields therapy + gemcitabine + nab-paclitaxel in 1L locally advanced pancreatic cancer TOP-LINE DATA ANTICIPATED Q4 2024 © 2024Novocure GmbH 16

  17. Slide 17: Pipeline of ongoing trials

    PHASE 3 METIS TTFields monotherapy treating brain metastases NON-SMALL CELL from Nscic LUNG CANCER LUNAR-2 TTFields + pembrolizumab + chemot treating 1L metastatic NSCLC PHASE 2 KEYNOTE-B36 TTFields therapy + pembrolizumab treating 1L advanced or metastatic NSCL' LUNAR-4 TTFields + ICI treating 2L m

  18. Slide 18: Prioritizing growth and path to profitability

    prioritizing growth and path to profitability OPTIMIZED OPERATIONS Funding future without increased cash burn ACCELERATE PATH TO PROFITABILITY forward © 2024NovocureGmbH 18

  19. Slide 19: Significant pipeline catalysts on foundation of positive cashflow business

    novecure’ Significant pipeline catalysts on foundation of positive cashflow business METIS DATA LUNG APPROVALS & LAUNCH PANOVA-3 DATA PROFITABLE GBM BUSINESS patientforward® = : © 2024 Novocure GmbH 19

  20. Slide 20: Appendix

    novecure’ appendix patientforward”

  21. Slide 21: Therapy is frequency-tuned to target dividing cancer cells

    novecure’ therapy is frequency-tuned to target dividing cancer cells }H————__— TUMOR TREATING FIELDS 150 kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablation ionizing pacemaker Tumor Treating rad

  22. Slide 22: TTFields have multiple, distinct mechanisms of action

    novecure’ TTFields have multiple, distinct mechanisms of action interference of cell movement and migration disruption of mitosis “ a mechanisms work ° together to selectively target and disrupt the progression of cancer cells, which can lead downregulation of . to their death downstream enhancement

  23. Slide 23: Optimized dose delivered can lead to increased efficacy

    novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE Wins stato DELIVERED TO TUMOR OF TISSUE —a TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om, patientfo rward™ © 2024 Novocure GmbH 23 Ballo MT, et a. Correlation of Tumor Treating Fields Dosimetry to Survival O

  24. Slide 24: New lighter, thinner arrays deliver greater intensity

    novecure’ new lighter, thinner arrays deliver greater intensity an EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps 0 V/cm PMA SUPPLEMENT SUBMITTED IN @4 2023 patientforwa rd” © 2024Novocure GmbH 24 obtained from pa

  25. Slide 25: Ongoing trial designs

    novecure’ ongoing trial designs © patientfo rward” © 2024 Novocure GmbH 25

  26. Slide 26: METIS: phase 3 trial in brain metastases from NSCLC

    novecure’ METIS: phase 3 trial in brain metastases from non- small cell lung cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* stereotactic Se Tumor Treating Fields — MRI q2m until radiosurgery progression screening and baseline ii evaluation stereotactic MRI i ‘EEE EE _ STUDY DESIGN * 270 patients with 1

  27. Slide 27: PANOVA-3: phase 3 trial in locally advanced pancreatic cancer

    novecure’ PANOVA-3: phase 3 trial in locally advanced pancreatic cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* screening and EZ baseline evaluation STUDY DESIGN 556 patients with 18-month minimum follow-up Primary endpoint: overall survival TTFields + nab-paclitaxel + gemcitabine post-PD follow up vis

  28. Slide 28: PANOVA-4: phase 2 trial in metastatic pancreatic cancer

    novecure’ PANOVA-4: phase 2 trial in metastatic pancreatic cancer PILOT, SINGLE-ARM TRIAL DESIGN! TTFields + screening and baseline J = atezolizumab+ [im CT q8w until | - post-PD _ survival evaluation nab-paclitaxel + progression follow up visit follow-up q3m gemcitabine STUDY DESIGN + 76 patients w

  29. Slide 29: TRIDENT: phase 3 trial in newly diagnosed glioblastoma

    TRIDENT: phase $ trial in newly diagnosed glioblastoma OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + radiation TTFields + therapy + TMZ maintenance TMZ screening and baseline evaluation Radiation therapy TTFields + +TMZ maintenance TMZ = = 9 ro a = re} nol = fw STUDY DESIGN 950 patients with 24-mo

  30. Slide 30: LUNAR-2: phase 3 trial in metastatic NSCLC

    novecure’ LUNAR-2: phase 3 trial in metastatic non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN TTFields + pembrolizumab + CT/follow-up q3w survival until progression follow-up platinum-based chemotherapy screening and baseline evaluation pembrolizumab + platinum-based CT/follow-up q3w

  31. Slide 31: KEYNOTE B36: phase 2 trial in NSCLC

    novecure’ KEYNOTE B36: phase 2 trial in locally advanced or metastatic non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN? =I a . follow-up q survival 5 Y TTFields + pembrolizumab a qow follow-up screening and baseline = evaluation PS N & \ r follow-up q3w, survival £ pembrolizumab = gow

  32. Slide 32: Optune Lua and Optune Gio indications for use and important safety information

    novecure’ Optune Lua® and Optune Gio® indications for use and important safety information INDICATIONS + Optune Gio is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM) o Optune Gio with temozolomide is indicated for the

  33. Slide 33: Optune Lua and Optune Gio warnings and precautions

    novecure’ Optune Lua® and Optune Gio® indications for use and important safety information WARNINGS AND PRECAUTIONS * Optune Gio and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adver

Novocure — Investor Presentation (February 2024) on 6ix